Criscuolo Daniela, Morra Francesco, Celetti Angela
Institute for the Experimental Endocrinology and Oncology, Research National Council, CNR, 80131 Naples, Italy.
Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.
Explor Target Antitumor Ther. 2022;3(5):570-581. doi: 10.37349/etat.2022.00101. Epub 2022 Oct 25.
Solute carrier family 7 member 11 (SLC7A11; also known as xCT), a key component of the cystine/glutamate antiporter, is essential for the maintenance of cellular redox status and the regulation of tumor-associated ferroptosis. Accumulating evidence has demonstrated that xCT overexpression, resulting from different oncogenic and tumor suppressor signaling, promotes tumor progression and multidrug resistance partially via suppressing ferroptosis. In addition, recent studies have highlighted the role of xCT in regulating the metabolic flexibility in cancer cells. In this review, the xCT activities in intracellular redox balance and in ferroptotic cell death have been summarized. Moreover, the role of xCT in promoting tumor development, drug resistance, and nutrient dependency in cancer cells has been explored. Finally, different therapeutic strategies, xCT-based, for anti-cancer treatments have been discussed.
溶质载体家族7成员11（SLC7A11；也称为xCT）是胱氨酸/谷氨酸反向转运体的关键组成部分，对维持细胞氧化还原状态和调节肿瘤相关的铁死亡至关重要。越来越多的证据表明，由不同的致癌和肿瘤抑制信号导致的xCT过表达，部分通过抑制铁死亡促进肿瘤进展和多药耐药性。此外，最近的研究突出了xCT在调节癌细胞代谢灵活性方面的作用。在这篇综述中，总结了xCT在细胞内氧化还原平衡和铁死亡细胞死亡中的活性。此外，还探讨了xCT在促进肿瘤发展、耐药性和癌细胞营养依赖性方面的作用。最后，讨论了基于xCT的不同抗癌治疗策略。
